Success Stories: A Scientist III Secured both his NIW and EB1-A Approvals in the Field of Computational Biology with our Persistent Support

 

Client’s Testimonial:

“Thank you for the messages about my case approval! I am very happy to hear the outcome. You are very professional and did great work on my case. I have referred you to my friends in the past and will continue to refer you in the future! Thank you!”

---

On May 19^th, 2021 and January 5^th, 2022, we received another EB2-NIW (National Interest Waiver) and EB-1A (Alien of Extraordinary Ability) approval for a Scientist III in the Field of Computational Biology (Approval Notice).

---

General Field: Computational Biology

Position at the Time of Case Filing: Scientist III

Country of Origin: China

State of Residence at the Time of Filing: Connecticut

Approval Notice Date: May 19^th, 2021 (NIW) and January 5^th, 2022 (EB-1A)

Processing Time: 14 months, 8 days (NIW) and 13 days (EB-1A) (Premium Processing Requested)

---

Case Summary:

A petition for an employment-based immigration visa under the second preference (“EB-2”), unlike the first preference category of individuals with extraordinary ability, (“EB1-A”), at least requires:

• No specific job offer/labor certification is required for a foreign person as long as he/she is entering the United States to continue work in the field in which he/she has an extraordinary ability, therefore self-petition is allowed.
• Evidence of original contributions, usually through publication, of major significance in the foreign national’s field of science, scholastic, artistic, or athletic.
• Performance in a significant role for organizations or establishments that have a distinguished reputation.
• Receipt of a higher salary or remuneration than is usual in the field.
• Other comparable evidence if the above types of evidence do not readily apply to the foreign national’s occupation.

Therefore, when a scientist III from China holding a Ph.D. in biology approached us to file both his I-140 NIW and EB1-A petitions, we assimilated the following essentials from his academic and professional records:

• His biology and biomedical informatics research address some of our nation’s and the world’s most pressing issues, including the health and economic burden of neurodegenerative diseases, immune diseases, and many inherited diseases. He is particularly well-known for his contributions to the expansion of a widely used biomedical ontology.
• His research has resulted in 9 peer-reviewed scientific articles, being cited 609 times in at least 45 countries according to Google Scholar.
• He has conducted at least 75 reviews for at least 7 journals.
• His research has been funded by notable organizations like the National Institutes of Health and the American Heart Association.

Therefore, our client’s research is viewed as significantly useful to the United States’ national interests of advancing knowledge in biosciences and improving public health.

• 4 fellow experts in the field provided further comprehension of the importance of his ongoing work in the field, one of whom stated:

“[Client’s] research is important to the United States because several chronic diseases are linked to the improper function of regulated exocytosis, including type-2 diabetes and asthma…[Client’s] findings confirm that GENE X plays a substantial role in retrograde trafficking in the cells and offers a new avenue for diabetes drug design. His research, therefore, concerns the betterment of the U.S. medical community and type-2 diabetes patients.”

Consequently, he not only received his NIW approval with the help of our teammates but even acquired his EB1-A (Alien of Extraordinary Ability) approval in just 13 days (thanks to premium processing). We are glad to have had the opportunity to represent him in this case and wish him good fortune and a prosperous future.

---